**Merck's Keytruda Leads 2023 Sales!**

Merck's Keytruda emerges as the top-selling drug of 2023, amassing an impressive $25 billion in sales. Merck CFO Caroline Litchfield attributes Keytruda's surge in 2023 to recent approvals for early-stage cancer treatments.

Keytruda accounted for 41.6% of Merck’s revenue in 2023.

However, Novo Nordisk’s semaglutide diabetes and obesity treatments Ozempic, Wegovy, and Rybelsus could pose competition in the near future.

Stay updated with #Globalbio.

Read more: https://lnkd.in/gvC2C_G7